Author

L. Leitner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. I. Matter· 2 shared J. Baggenstos· 2 shared J. Du· 2 shared L. Hunold· 2 shared M. Dunne· 2 shared M. J. Loessner· 2 shared P. Piffaretti· 2 shared S. Kilcher· 2 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. I. Matter

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Engineered reporter phages for rapid detection of Escherichia coli, Klebsiella spp., and Enterococcus spp. in urine

S. Meile, J. Du, S. Staubli, S. Grossmann, H. Koliwer-Brandl, P. Piffaretti, L. Leitner, C. I. Matter, J. Baggenstos, L. Hunold, S. Milek, C. Guebeli, M. Kozomara-Hocke, V. Neumeier, A. Botteon, , S. Kilcher

This study develops a rapid phage-based diagnostic assay to detect E. coli, Klebsiella spp., and Enterococcus spp. in urine with high sensitivity and specificity within 5 hours.

bioRxiv · Nov 23, 2022 · PreprintMicrobiology

Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors

J. Du, S. Meile, J. Baggenstos, T. Jaeggi, P. Piffaretti, L. Hunold, C. I. Matter, L. Leitner, T. M. Kessler, M. J. Loessner, S. Kilcher, M. Dunne

This paper develops heterologous effector phage therapeutics (HEPTs) to enhance bacteriophage treatment of UTIs by delivering colicin-like effectors that suppress resistance and improve bacterial killing.

bioRxiv · Mar 9, 2022 · PreprintBioengineering

Dual Phenotype Of MDA-MB-468 Cancer Cells Reveals Mutual Regulation Of Tensin3 And Adhesion Plasticity

A. Vess, U. Blache, L. Leitner, A. R. M. Kurz, A. Ehrenpfordt, M. Sixt, G. Posern

The paper identifies tensin3 as a determinant of adhesion plasticity in MDA-MB-468 cancer cells, showing its role in regulating the switch between adhesive and non-adhesive states.

bioRxiv · Apr 25, 2017Cell Biology